Publications 2023

Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA, Chekenya M, Goplen D (2023)
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
PLoS One, 18 (2), e0281166
DOI 10.1371/journal.pone.0281166, PubMed 36730349

Blakstad H, Mendoza Mireles EE, Heggebø LC, Magelssen H, Sprauten M, Johannesen TB, Vik-Mo EO, Leske H, Niehusmann P, Skogen K, Helseth E, Emblem KE, Brandal P (2023)
Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study
Neurooncol Pract, 11 (1), 36-45
DOI 10.1093/nop/npad063, PubMed 38222046

Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström P et al. (2023)
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
BMJ Open, 13 (3), e070071
DOI 10.1136/bmjopen-2022-070071, PubMed 36940951

Leske H, Blakstad H, Lund-Iversen M, Skovholt EK, Niehusmann P, Ramm-Pettersen JT, Skogen K, Kongelf G, Sprauten M, Magelssen H, Brandal P (2023)
Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A
Neuropathology, 43 (5), 385-390
DOI 10.1111/neup.12895, PubMed 36754566

Publications 2022

Blakstad H, Wohlleben C, Saxhaug C, Brandal P (2022)
SMART syndrome: two cases highlighting a complex and rare complication of brain irradiation
BMJ Case Rep, 15 (9)
DOI 10.1136/bcr-2022-249599, PubMed 36167430